touchEXPERT OPINIONS for touchHAEMATOLOGY
Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).
The experts:
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novartis and is provided by touchIME.
For further information visit: www.touchhaematology.com/education/impact-of-new-guidelines-in-MDS-AML